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Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 
but not 5-HT2A/2C bindings in rat brains 
Abstract 
Olanzapine is widely prescribed for treating schizophrenia and other mental disorders, although it leads to 
severe body weight gain/obesity. Chronic co-treatment with betahistine has been found to significantly 
decrease olanzapine-induced weight gain; however, it is not clear whether this co-treatment affects the 
therapeutic effects of olanzapine. This study investigated the effects of chronic treatment of olanzapine 
and/or betahistine on the binding density of the serotonergic 5-HT2A (5-HT2AR) and 5-HT2C (5-HT2CR) 
receptors, 5-HT transporter (5-HTT), and dopaminergic D2 receptors (D2R) in the brain regions involved in 
antipsychotic efficacy, including the prefrontal cortex (PFC), cingulate cortex (Cg), nucleus accumbens 
(NAc), and caudate putamen (CPu). Rats were treated with olanzapine (1 mg/kg, t.i.d.) or vehicle for 3.5 
weeks, and then olanzapine treatment was withdrawn for 19 days. From week 6, the two groups were 
divided into 4 groups (n = 6) for 5 weeks' treatment: (1) olanzapine-only (1 mg/kg, t.i.d.), (2) betahistine-
only (9.6 mg/kg, t.i.d.), (3) olanzapine and betahistine co-treatment (O + B), and (4) vehicle. Compared to 
the control, the olanzapine-only treatment significantly decreased the bindings of 5-HT2AR, 5-HT2CR, and 
5-HTT in the PFC, Cg, and NAc. Similar changes were observed in the rats receiving the O + B co-
treatment. The olanzapine-only treatment significantly increased the D2R binding in the Cg, NAc, and CPu, 
while the betahistine-only treatment reduced D2R binding. The co-treatment of betahistine reversed the 
D2R bindings in the NAc and CPu that were increased by olanzapine. Therefore, chronic O + B co-
treatment has similar effects on serotonin transmission as the olanzapine-only treatment, but reverses 
the D2R that is up-regulated by chronic olanzapine treatment. The co-treatment maintains the therapeutic 
effects of olanzapine but decreases/prevents the excess weight gain. 
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Abstract 
Olanzapine is widely prescribed for treating schizophrenia and other mental disorders 
although it leads to severe body weight gain/obesity. Chronic co-treatment with betahistine 
has been found to significantly decrease olanzapine-induced weight gain; however it is not 
clear whether this co-treatment affects the therapeutic effects of olanzapine. This study 
investigated the effects of chronic treatment of olanzapine and/or betahistine on the binding 
density of the serotonergic 5-HT2A (5-HT2AR) and 5-HT2C (5-HT2CR) receptors, 5-HT 
transporter (5-HTT), and dopaminergic D2 receptors (D2R) in the brain regions involved in 
antipsychotic efficacy, including the prefrontal cortex (PFC), cingulate cortex (Cg), nucleus 
accumbens (NAc), and caudate putamen (CPu). Rats were treated with olanzapine (1 mg/kg, 
t.i.d.) or vehicle for 3.5 weeks, and then olanzapine treatment was withdrawn for 19 days. 
From week 6, the two groups were divided into 4 groups (n=6) for 5 weeks’ treatment: (1) 
olanzapine-only (1 mg/kg, t.i.d.), (2) betahistine-only (9.6 mg/kg, t.i.d.), (3) olanzapine and 
betahistine co-treatment (O+B), and (4) vehicle. Compared to the control, the olanzapine-
only treatment significantly decreased the bindings of 5-HT2AR, 5-HT2CR, and 5-HTT in the 
PFC, Cg and NAc. Similar changes were observed in the rats receiving the O+B co-treatment. 
The olanzapine-only treatment significantly increased the D2R binding in the Cg, NAc, and 
CPu, while the betahistine-only treatment reduced D2R binding. The co-treatment of 
betahistine reversed the D2R bindings in the NAc and CPu that were increased by olanzapine. 
Therefore, the chronic O+B co-treatment has similar effects on serotonin transmission as the 
olanzapine-only treatment, but reverses the D2R that is up-regulated by chronic olanzapine 
treatment. The co-treatment maintains the therapeutic effects of olanzapine but decreases / 
prevents the excess weight gain. 
 
Key Words: olanzapine; betahistine; dopamine receptor; serotonin receptor; receptor binding 
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1. Introduction 
Second generation antipsychotic drugs (SGAs) such as olanzapine have improved tolerability 
compared with first generation antipsychotic drugs (FGAs) as they produce fewer 
extrapyramidal symptoms (EPS) (Leucht et al., 2009). However, SGAs, such as olanzapine, 
can induce severe body weight gain and obesity side-effects (Lambert, 2011, Deng, 2013). 
For example, the CATIE (The Clinical Anti-psychotic Trials of Intervention Effectiveness) 
study reported that olanzapine caused significant weight gain (>7% from baseline) in highest 
proportion of chronic schizophrenia patients (30%) and amount of weight gain (average 
0.9kg/month) over an 18 months period, compared with quetiapine (16% and 0.23kg/month 
respectively), risperidone (14% and 0.18kg/month respectively) and ziprisidone (7% and 0.14 
kg/month respectively) (Lieberman et al., 2005). Furthermore, the CAFE (Comparison of 
Atypical Anti-psychotics for First Episode) study showed that the 80% of olanzapine-treated 
patients had significant weight gain (average 1.76 kg/month), compared with 57.6% of 
risperidone (average 1.28 kg/month), and 50% of quetiapine (average 1.29 kg/month) (Patel 
et al., 2009) after 52 weeks’ treatment (Patel et al., 2009). Compared with FGAs, olanzapine 
is a less potent antagonist at the dopamine D2 receptor (D2R), having a pharmacological 
binding profile by binding at a wide range of non-dopaminergic G-protein-coupled receptors 
including serotonin 5-HT2A (5-HT2AR) and 5-HT2C (5-HT2CR), histamine H1 (H1R) and 
muscarinic M1 receptors (Nasrallah, 2008, Lian et al., 2013). Among these receptors, the 
dopamine D2 and 5-HT2 receptors play critical roles in the therapeutic effects of olanzapine 
and other SGAs (Meltzer and Massey, 2011, Ginovart and Kapur, 2012). 
  
Dopamine receptor occupation (which for most antipsychotics is within the range of 65-78%), 
especially at the D2R, is crucial to achieve the optimal therapeutic effects of most 
antipsychotics with minimal EPS (Seeman, 2011, Ginovart and Kapur, 2012). Three major 
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dopaminergic pathways involved in the actions of antipsychotics, which are the mesolimbic, 
mesocortical, and nigrostriatal pathways (Kapur and Mamo, 2003). D2R blockade of the 
mesolimbic pathway, in which dopaminergic neurons project from the ventral tegmental area 
(VTA) to the nucleus accumbens (NAc), is the major mechanism by which antipsychotics 
control positive schizophrenia symptoms (Seeman, 2011, Ginovart and Kapur, 2012). The 
mesocortical pathway, in which the dopaminergic neurons project from the VTA to the cortex, 
including the prefrontal cortex (PFC) and cingulate cortex (Cg), is involved in the cognitive 
deficits and the negative symptoms of schizophrenia (Volk, 2010, Ginovart and Kapur, 2012); 
By contrast, EPS are related to the D2R blockade in the nigrostriatal pathway, in which 
dopaminergic neurons project from the substantia nigra (SN) to the caudate putamen (CPu) 
(Ginovart and Kapur, 2012). However, recent evidence indicates that the nigrostriatal 
pathway is also involved in the pathophysiology of schizophrenia and antipsychotic treatment 
(Howes et al., 2012).  
 
Serotonin receptors such as 5-HT2AR and 5-HT2CR are G protein-coupled receptors which are 
linked to an intracellular molecular signal-transduction cascade, and which have been 
implicated in the therapeutics of SGAs and various neuropsychiatric disorders (Horacek et al., 
2006, Meltzer and Massey, 2011). It has been hypothesized that a relatively high 5-HT2AR 
antagonistic affinity compared to the D2R is the basis for the difference between the majority 
of SGAs and FGAs (Meltzer and Massey, 2011), although some of SGAs (such as 
Amisulpride) have low affinity for 5-HT2AR (Leucht et al., 2009). Additionally, the high 5-
HT2AR and 5-HT2CR affinity of most SGAs including olanzapine has been demonstrated to 
facilitate dopamine release in the PFC and hippocampus (Kuroki et al., 2008). The 5-HT2CR 
antagonists may increase dopamine levels in the NAc and PFC (Di Matteo et al., 2001). 
There is evidence that a combination of 5-HT2AR and 5-HT2CR blockades is more efficient 
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than the 5-HT2AR blockade alone at increasing dopamine release in the NAc and PFC, which 
would improve cognitive deficits (Horacek et al., 2006). Therefore, the functional 
combination of the 5-HT2 and D2 receptors is crucial to the therapeutic efficacy of olanzapine. 
 
The histaminergic H1R is involved in the regulation of body weight, food intake and energy 
expenditure, which is a key contributor for body weight gain induced by olanzapine (a potent 
H1R antagonist) (Kim et al., 2007, Deng et al., 2010). Our previous study targeting the H1R 
showed that short-term (2 weeks) co-treatment of betahistine (an H1R agonist and H3R 
antagonist) and olanzapine can reduce about 45% the body weight gain induced by 
olanzapine treatment in drug-naïve rats (Deng et al., 2012). Consistently, the co-treatment of 
olanzapine, betahistine and reboxetine (a selective norepinephrine reuptake inhibitor) was 
found to reduce the olanzapine-induced weight gain following short-term (6 weeks) treatment 
in first-episode schizophrenia patients (Poyurovsky et al., 2013). Importantly, patients with 
schizophrenia or other mental disorders (such as bipolar disorder) often face chronic and 
repeated treatments with antipsychotics. Antipsychotic treatments induce severe weight gain 
not only in drug-naïve patients, but also in chronic patients with previous antipsychotic 
exposure and repeated treatments (Lieberman et al., 2005). In a chronic rat model with 
repeated olanzapine exposure, we recently found that chronic (5 weeks) co-treatment with 
betahistine is also effective in reducing olanzapine-induced weight gain (Lian et al., 2014).  
 
A key issue is whether chronic betahistine co-treatment affects the therapeutic efficacy of 
olanzapine. Our previous study found that a short-term (2 weeks) co-treatment of olanzapine 
and betahistine does not influence the effect of olanzapine on dopamine D2 and 5-HT2AR 
bindings in the PFC, Cg, NAc, CPu, SN, and VTA in drug naïve rats (Lian et al., 2013). This 
may explain why betahistine does not affect the therapeutic efficacy of olanzapine observed 
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in short-term therapy in first-episode, drug-naïve schizophrenia patients (Poyurovsky et al., 
2005, Lian et al., 2013). However, in the clinic, chronic schizophrenia patients normally have 
previously experienced antipsychotic exposure when they are prescribed an antipsychotic 
treatment. Therefore, we mimicked the repeated treatment condition in which rats had an 
early olanzapine exposure and was followed by chronic treatment of olanzapine and/or 
betahistine. Since it is not clear whether chronic co-treatment with betahistine affects the 
therapeutic effects in chronic patients with repeated second generation antipsychotics (SGAs) 
treatments, or affects the D2R and 5-HT2R neurotransmission, this study investigated the 
effects of chronic co-treatment of olanzapine and betahistine on the 5-HT2AR, 5-HT2CR and 
D2R binding in a rat model with repeated olanzapine treatment. 
 
2. Experimental Procedures 
2.1. Animal treatment and administration  
Female Sprague Dawley rats (201-225g) were obtained from the Animal Resources Centre 
(Perth, WA, Australia).  After one week of habituation, they were housed individually with 
ad-libitum access to water and standard laboratory chow (3.9 kcal/g; 10% fat, 74% 
carbohydrate, 16% protein) at 22°C under a 12 hour light-dark cycle (light cycle from 07:00-
19:00 and dark cycle from 19:00-07:00) throughout the study (Deng et al., 2012, Lian et al., 
2013). The animals were then trained for one week to self-administer specially prepared 
cookie-dough pellets by metal spoon without the drug (0.3 g) and handled to minimise stress 
throughout the experiment. The drug powder containing cornstarch (30.9%), sucrose (30.9%), 
gelatine (6.3%), casein (15.5%), fibre (6.4%), minerals (8.4%) and vitamins (1.6%), and then 
mixed with water (Deng et al., 2012). Rats were randomly administered different drugs 3 
times per day orally (07:00, 15:00, 23:00 h). Briefly (Figure 1), rats were treated with 
olanzapine (1 mg/kg, t.i.d., n=12) or vehicle (n=12) for 3.5 weeks, and the drug treatment 
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was then withdrawn from Day 23 for 19 days. From week 6, the two groups were divided 
into 4 groups (n=6) for further treatment for 5 weeks: (1) olanzapine (1 mg/kg, t.i.d.), (2) 
betahistine (9.6 mg/kg, t.i.d.), (3) co-treatment of olanzapine and betahistine (same doses as 
above), and (4) control (vehicle). The olanzapine dosage used is equivalent to the 
recommended dosage for treating schizophrenia patients, and it was translated based on body 
surface area according to the FDA guidelines for clinical trials (FDA, 2005, Reagan-Shaw et 
al., 2008). This dosage is behavioural and pharmacologically effective (Weston-Green et al., 
2011, Deng et al., 2012, Lian et al., 2013). The betahistine dosage can effectively decrease 
body weight gain (Szelag et al., 2001, Tarricone et al., 2010). In the rat, the half-lives of 
olanzapine are 2.5 hours and 5.1 hours in the plasma and brain, respectively, and they are 
maintained at a high level for 8 hours (Aravagiri et al., 1999). However, in humans, the half-
life of olanzapine in plasma is 24.2 hours, compared to 72 hours in the brain (Tauscher et al., 
2002). Betahistine has 3-4 hours of plasma half-life in humans with one day of urine 
excretion, but no data have shown the half-life of betahistine in rats (Botta et al., 2001). All 
of the experimental procedures were approved by the Animal Ethics Committee, University 
of Wollongong, Australia (AE11/10); and complied with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes (2004).  
 
2.2. Histology 
Forty eight hours after the last drug treatment, and the following euthanasia, the brain tissue 
was immediately removed, frozen in liquid nitrogen, and stored at -80°C until analysis. Six 
brains were randomly selected from each treatment group and sectioned coronally at -18 °C 
into 14 μm using a cryostat (Leica CM1850, Leica Microsystems, Germany) for receptor 
autoradiography. Sections were thaw-mounted onto Polysine™ Microscope Slides (Menzel 
GmbH & Co. KG, Braunschweig, Germany) and stored at -20 °C. A set of sections from each 
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animal was stained with 0.5% cresyl violet solution (Nissl staining) and used to confirm of 
anatomical structures. 
                                                                                                                                                                                                                                                
2.3. Receptors autoradiography and quantification 
2.3.1. Receptors autoradiography 
Procedures for [³H]ketanserin binding to the 5-HT2AR has been successfully performed in our 
laboratory (Kang et al., 2009, Lian et al., 2013). Briefly, brain sections were thawed and then 
pre-incubated for 15 minutes in 170 mM Tris buffer (pH 7.4) at room temperature. For total 
binding, sections were incubated with 2 nM [³H]ketanserin (Specific activity: 67 Ci/mmol; 
PerkinElmer, Walthm, MA, USA) in 170 mM Tris buffer for 2 hours at room temperature. 
Non-specific binding was determined by incubating subsequent sections with 2 nM 
[³H]ketanserin and 2 μM spiperone (Sigma Pharmaceuticals, Melbourne, VIC, Australia). 
Sections were washed in Tris buffer (pH 7.4) four times for 2 minutes at 4°C, dipped in ice-
cold milliQ H2O water to remove buffer salts, and then gently air dried under a stream of cool 
air. 
 
The procedures for bindings of [³H]mesulergine (to 5-HT2CR and 5-HT2AR), [³H]paroxetine 
(to 5-HTT) and [³H]raclopride (to D2R) autoradiography are well established in our 
laboratory and are similar to the 5-HT2AR binding procedures as described above. In brief, 
the brain sections were incubated with 5 nM [³H]mesulergine (84.5 Ci/mmol), 0.6 nM 
[³H]paroxetine (20.8 Ci/mmol) and 5nM [³H]raclopride (60.1 Ci/mmol) (PerkinElmer), 
respectively. Non-specific binding are detected at the presence of 100 nM spiperone and 10 
μM mianserin for [³H]mesulergine binding, 10 µM fluoxetine for  [³H]paroxetine binding, 
and 10 µM butaclamol for [³H]raclopride binding (du Bois et al., 2006, du Bois et al., 2008, 
Lian et al., 2013). 
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2.3.2. Quantitative analysis of autoradiography  
All of the receptor binding slides were exposed to Kodak BioMax MR film for 2-3 months, 
together with autoradiographic standards ([³H]microscales from Amersham), in X-ray film 
cassettes. This was followed by the analysis of binding images using the Multi-Analyst image 
analysis system (Bio-Rad, USA), connected to a GS-800 Imaging Densitometer (Bio-Rad, 
USA). The specific binding was calculated by subtracting non-specific binding from total 
binding. A set of sections from each animal were stained with 0.5% cresyl violet solution 
(Nissl staining) and used to confirm anatomical structures. Specific brain regions in this 
project were identified by reference to the Nissl-stained sections and a standard rat brain atlas 
(Paxinos and Watson, 2007).  
 
2.4. Statistical analysis 
Statistical analysis was performed using SPSS (IBM version 19.0, SPSS Inc., NY, USA). The 
Kolmogorov-Smirnov test was used to examine whether data from all experiments are 
normally distributed. Two-way ANOVAs (OLANZAPINE × BETAHISTINE) were used to 
analyse receptor binding density in the relevant rat brain regions. The post-hoc Dunnett-T test 
was used to analyse the relationships among the measurements. The Mann-Whitney U test 
was applied to the data without abnormal distribution. All data were expressed as mean ± 
SEM, and statistical significance was accepted when p<0.05. 
 
3. Results   
Body weight and energy data have been reported previously (Lian et al., 2014). Briefly, the 
olanzapine-only treatment significantly increased weight gain and food intake/feeding 
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efficiency, while the co-treatment of olanzapine and betahistine significantly reduced about 
51% weight gain and feeding efficiency compared to the olanzapine-only treatment (Lian et 
al., 2014). 
 
3.1. [³H]ketanserin binding to 5-HT2AR  
Two-way ANOVAs revealed the significant effects of the OLANZAPINE factor on 5-HT2AR 
in the PFC (F1,20=36.028, p<0.001), Cg (F1,20=10.691, p=0.004), NAc core (NAcC) 
(F1,20=15.663, p=0.005), NAc shell (NAcS) (F1,20=6.224, p=0.021), and SN (F1,20=7.046, 
p=0.015). However, there was no significant effect of the BETAHISTINE factor in these 
brain nuclei, and, there was no significant interaction between the two factors (all p>0.05). 
 
The olanzapine-only treatment significantly influenced the levels of 5-HT2AR binding density 
(Table 1). Post-hoc analysis identified a significant decrease in 5-HT2AR binding in the PFC, 
Cg, NAcC, NAcS (all p<0.01), and SN (p<0.05) in the rats receiving the olanzapine-only 
treatment (Table 1). The olanzapine-only treatment did not significantly decrease 5-HT2AR 
binding in the VTA (p>0.05; Table 1). Compared to the control, the levels of 5-HT2AR 
binding density were also significantly decreased by O+B co-treatment in the PFC, Cg, 
NAcC and NAcS (all p<0.01), but not in the VTA and SN (p>0.05; Table 1). However, there 
were no significant differences in 5-HT2AR binding between the olanzapine-only and O+B 
co-treatment groups in these brain regions (all p>0.05, Table 1). In addition, the betahistine-
only treatment did not affect 5HT2AR binding compared to the control (all p>0.05; Table 1). 
 
3.2. [³H]mesulergine binding to 5-HT2CR and 5-HT2AR     
The altered of [³H]mesulergine binding density induced by olanzapine was observed in 
several brain regions (Table 2). Two-way ANOVAs showed a significant effect of the 
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OLANZAPINE factor on [³H]mesulergine binding density in the PFC (F1,20=17.918, 
p<0.001), Cg (F1,20=64.387, p<0.001), NAcC (F1,20=15.576, p=0.001), and NAcS 
(F1,20=17.384, p<0.001). There was a tendency to significance of the OLANZAPINE factor 
on [³H]mesulergine binding in the CPu (F1,20=4.145, p=0.055). However, there were no 
significant effects of the BETAHISTINE factor and no interaction between the two factors 
(all p>0.05). 
 
Post-hoc analysis revealed that significant attenuation of the [³H]mesulergine binding density 
was caused by the olanzapine-only treatment in the PFC, Cg, NAcC, and NAcS (all p<0.01) 
compared with the control, but not in the CPu and SN (p>0.05) (Table 2). Furthermore, 
compared with the control, the [³H]mesulergine binding level was also significantly 
decreased by the co-treatment with O+B in the PFC and CPu (p<0.05), and the Cg, NAcC, 
and NAcS (p<0.01) (Table 2). However, there was no significant difference in the 
[³H]mesulergine binding between the co-treatment of O+B and the olanzapine-only treatment, 
or between the control and betahistine-only groups (Table 2).  
 
3.3. [³H]paroxetine binding to 5-HTT binding    
Two-way ANOVAs revealed the significant effects of the OLANZAPINE factor in the Cg 
(F1,20=18.189, p<0.001), NAcC (F1,20=9.862, p=0.005) and NAcS (F1,20=22.853, p<0.001). 
There was borderline significance for the OLANZAPINE factor in the PFC (F1,20=4.076, 
p=0.057). However, there was no significant effect of the BETAHISTINE factor, and no 
interaction between the two factors. 
 
The 5-HTT binding density was significantly lower in the olanzapine-only group than in the 
controls in the PFC and NAcC (p<0.05), as well as the Cg and NAcS (all p<0.01). Similar to 
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the olanzapine-only treatment, the co-treatment of O+B also significantly decreased 5-HTT 
binding in the Cg (p<0.01) and NAcS (p<0.05) compared with the control, and tended to 
decrease 5HTT binding in the PFC (p=0.059) and NAcC (p=0.089) (Table 3). However, the 
olanzapine-only and O+B co-treatment had no effect on the 5-HTT binding in the CPu and 
VTA (Table 3). Furthermore, there was no significant difference between the olanzapine-only 
treatment and the co-treatment of O+B. Also, the betahistine-only treatment did not affect the 
5-HTT binding in any of the brain region (Table 3). 
 
3.4. [³H]raclopride binding to D2R  
Two-way ANOVAs (OLANZAPINE × BETAHISTINE) revealed significant effects of the 
OLANZAPINE factor on the PFC (F1,20=5.857, p=0.025), NAcC (F1,20=20.631, p<0.001), 
NAcS (F1,20=19.065, p<0.001), Cg (F1,20=10.924, p=0.004) and CPu (F1,20=21.025, p<0.001), 
as well as significant effects of the BETAHISTINE factor on the NAcC (F1,20=6.438, 
p=0.020), NAcS (F1,20=4.802, p=0.040) and CPu (F1,20=8.690, p=0.008). However, no 
significant interaction was detected between the two factors.  
 
Post-hoc tests showed that the olanzapine-only treatment significantly increased D2R binding 
density in the NAcC, NAcS and CPu (all p<0.01), as well as the Cg (p<0.05), while it tended 
to increase D2R binding in the PFC (p=0.076). The betahistine-only treatment significantly 
decreased D2R binding density in the CPu and NAcC (p<0.05) compared to the control 
(Table 4). The co-treatment of the O+B group had a significantly lower D2R binding levels in 
the NAcC (p<0.01) and NAcS (p<0.05) than the olanzapine-only treatment group. The O+B 
co-treatment group had no significant change in D2R binding in the CPu compared with the 
olanzapine-only group (p=0.107) (Table 4).  
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4. Discussion 
The present study using female rats provides the first evidence of the effects of chronic 
olanzapine and/or betahistine treatment on the 5-HT2AR, 5-HT2CR, 5-HTT and D2R bindings 
in the brain regions involved in the therapeutic efficacy of olanzapine. Olanzapine-only and 
O+B co-treatment had similar effects in down-regulating the 5-HT2AR, 5-HT2CR and 5-HTT 
binding density in various brain regions, particularly the PFC, NAcC, NAcS and Cg. In 
contrast, the D2R binding density was significantly up-regulated by the olanzapine-only 
treatment in the Cg, NAcC, NAcS and CPu, while it was down-regulated by the betahistine-
only treatment in the NAcC and NAcS, Importantly, the betahistine co-treatment reversed the 
D2R up-regulation induced by olanzapine in the NAcC and NAcS.  
 
The female rats were used in this study, because the olanzapine-induced weight gain model 
has been well established and validated in female rats in our and other laboratories (Choi et 
al., 2007, Weston-Green et al., 2011, Deng et al., 2012). Clinically, it is also a common 
observation that female patients have a much higher risk than males for SGA-induced weight 
gain side-effects (Gebhardt et al., 2009, Seeman, 2009, Weston-Green et al., 2010, Treuer et 
al., 2011). Furthermore, in this study, rats were closely housed in a room occupied by only 
female rats. Our pre-experiments have shown that, under this rearing condition, the estrus 
cycles of all female rats are synchronized (Lian et al., 2013). 
 
SGAs such as olanzapine and clozapine have been reported to attenuate 5-HT2AR binding and 
mRNA expression, which are involved in the therapeutic effects of SGAs (Tarazi et al., 2002, 
Lian et al., 2013). Coinciding with these findings, this study revealed that chronic olanzapine 
treatment significantly reduced 5-HT2AR binding density in the PFC, Cg, NAcC, NAcS and 
SN, strongly implicated in the therapeutics of antipsychotics (Kuroki et al., 2008, Meltzer and 
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Massey, 2011). Notably, the chronic O+B co-treatment had similar effects in down-
regulating 5-HT2AR binding as the olanzapine-only treatment in rats on chronic and repeated 
olanzapine treatment, although the chronic betahistine-only treatment did not affect 5-HT2AR 
binding. Consistent with findings in this study, our previous study found that short-term O+B 
co-treatment had similar down regulatory effects as the olanzapine-only treatment on 5-
HT2AR binding density in drug-naïve rats (Lian et al., 2013). These results suggest that both 
early olanzapine exposure and chronic betahistine co-treatment do not influence olanzapine’s 
actions on 5-HT2AR. 
 
Besides 5-HT2AR, most of SGAs have a high binding affinity with 5-HT2CR which is 
involved in the antipsychotic drug action (Meltzer and Massey, 2011). Several studies have 
revealed the association between the polymorphism of the 5-HT2CR gene/its promoter region 
and clinical response to antipsychotic (including olanzapine) treatment (Reynolds et al., 
2005). Similar to 5-HT2AR binding, the 5-HT2CR binding is down-regulated in response to 
olanzapine and other SGAs treatment (Tarazi et al., 2002, Zhang and Malhotra, 2011). In this 
study, [³H]mesulergine was used to examine 5-HT2CR density, although we should consider 
the limitation that [³H]mesulergine has also high affinity with 5-HT2AR (Abbas et al., 2009). 
Consistent with previous reports, this study revealed that decreased [³H]mesulergine binding 
density in the PFC, Cg, NAcC, and NAcS after chronic olanzapine treatment. It should also 
be noted that chronic O+B co-treatment had a similar attenuation effect as olanzapine-only 
treatment on the [³H]mesulergine binding, while the betahistine-only treatment had no 
significant effects on the [³H]mesulergine binding in these brain regions. Consequently, this 
study provided further evidence that chronic O+B co-treatment would have similar effects on 
5-HT translations through 5-HT2AR and 5-HT2CR. 
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As an integral membrane protein, 5-HTT terminates the action of serotonin by transporting 
serotonin from synaptic spaces into presynaptic neurons (Zhang and Malhotra, 2011, Lian et 
al., 2013). Variations in several 5-HTT gene polymorphisms have been associated with the 
response to olanzapine and other SGAs (Zhang and Malhotra, 2011). For example, a repeat 
length polymorphism 5-HTT-LPR (a 44bp insertion/deletion in the promoter region) has 
shown that the short allele of 5-HTT-LPR is associated with poor response to olanzapine, 
clozapine, and risperidone treatment (Vazquez-Bourgon et al., 2010, Zhang and Malhotra, 
2011). However, the exact role of 5-HTT in the olanzapine treatment of schizophrenia 
symptoms is still not clear. Our previous study revealed that short-term treatment of 
olanzapine and co-treatment of O+B down-regulated 5-HTT bindings in the SN and VTA of 
drug-naïve rats (Lian et al., 2013). In this study, chronic olanzapine treatment significantly 
decreased the 5-HTT binding density in the PFC, Cg, NAcC, and NAcS. The present results 
suggest that the 5-HT uptake in the PFC, Cg and NAc may contribute to therapeutic effects of 
chronic olanzapine treatment. In addition, a similar decrease of 5-HTT binding density was 
also revealed in rats with O+B co-treatment. Thus co-treatment with betahistine should not 
affect olanzapine’s action on 5-HTT. However, although 5-HTT binding was down-regulated 
in both short-term treatment in drug-naïve subjects and chronic olanzapine treatment, this 
effect occurred in different brain regions. Further study is necessary to determine the 
contributing factors (short-term vs. chronic or drug-naïve vs. repeated treatment) for these 
differences.  
 
In terms of D2R binding, in this study chronic olanzapine treatment (3 mg/kg/day, t.i.d.) up-
regulated the D2R binding levels in the Cg, NAcC, NAcS and CPu. This result corresponds to 
a previous report that chronic treatment of olanzapine (5mg/kg/day via osmotic minipumps) 
caused an increase in D2R binding in the PFC, CPu, and NAc (Tarazi et al., 2001). However, 
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olanzapine was found only having a tendency to increase D2R binding density in the PFC, but 
not significance in this study. It is worth noting that a previous study reported a significant 
increase of D2R binding in the PFC following 4 weeks treatment of olanzapine (Tarazi et al., 
2001). This discrepancy could be due to different radioactive ligands used in this 
([
3
H]Raclopride) and Tarazi et al. ([
3
H]nemonapride) studies, or most possibly a higher 
olanzapine dosage (5 mg/kg/day via osmotic minipump) used in Tarazi et al than in this study 
(3 mg/kg/day, t.i.d. via orally feeding in cookie dough) (Tarazi et al., 2001, Lian et al., 2014). 
In fact, some studies using olanzapine treatment at lower  doses (1-2mg/kg/day) or short-term 
treatment (~2 weeks) did not affect D2R binding (Han et al., 2009, Lian et al., 2013). It has 
been well documented in both humans and laboratory animals that D2R up-regulation induced 
by chronic antipsychotic (including olanzapine) treatment may lead to a state of 
“dopaminergic supersensitivity” (Samaha et al., 2007, Seeman, 2011). This “dopaminergic 
supersensitivity” is characterized by an increased vulnerability to psychosis (termed 
“antipsychotic-induced supersensitivity psychosis” in humans), and to psychomotor 
activating effects of the dopamine agonist, which may lead to treatment failure over time 
(Samaha et al., 2007). Furthermore, it is worth noting that chronic olanzapine treatment is 
still associated with some risks for EPS, although at a much lower rate than FGAs 
(Kantrowitz and Citrome, 2008). The D2R binding up-regulation in the CPu observed in the 
chronic olanzapine treatment in this and other studies may partially explain its risk for the 
development of EPS (Tarazi et al., 2001). It is interesting that this is the first study to reveal 
the effect of chronic betahistine treatment in decreasing D2R binding in the NAc and CPu, 
which was not observed in our previous study with a short-term (2-weeks) treatment at a 
lower dose (2.67mg/kg vs. 9.6mg/kg in this study) (Lian et al., 2013). The betahistine dosage 
(9.6 mg/kg) applied in this present study is equal to about 93 mg in human (60 kg body 
weight) based on dosage translation between species according to body surface area followed 
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the FDA guideline (FDA, 2005, Reagan-Shaw et al., 2008). Betahistine has 3-4 hours of 
plasma half-life in humans with one day of urine excretion (Botta et al., 2001). Although 
there is no data available for the half-life of betahistine in rats, it is reasonable to suppose that 
betahistine is most likely to have a shorter half-life in rats than in humans. This dosage (9.6 
mg/kg, t.i.d) should be relevant to the human dosage (48 mg, t.i.d.) used to attenuate 
olanzapine-induced weight gain in the clinical trials (Poyurovsky et al., 2005, Poyurovsky et 
al., 2013). Therefore, 9.6 mg/kg was used in this study, which should be appropriate for 
investigating the effect of co-treatment with betahistine in relieving olanzapine-induced body 
weight gain in rats. More importantly, co-treatment with betahistine significantly reversed 
D2R binding up-regulation in the NAc and there was a trend towards reversing it in the CPu. 
Therefore, co-treatment with betahistine may be able to reduce the “dopaminergic 
supersensitivity” and EPS caused by chronic antipsychotic (olanzapine) treatment, although 
further clinical studies are necessary. On the other hand, betahistine may affect olanzapine’s 
action on dopamine D2R. Notably, that histamine H3R can form intramembrane interactions 
with D2R (Ferrada et al., 2008), and negatively modulate dopaminergic transmission via 
interactions with D2R (Panula and Nuutinen, 2013). Since betahistine is a patent H3R 
antagonist (and also a H1R agonist), it is probable that the H3R antagonist property of 
betahistine plays a key role in attenuating the D2R binding density observed in this study.  
 
In summary, this study revealed the effects of chronic olanzapine and/or betahistine treatment 
on the 5-HT2AR, 5-HT2CR, 5-HTT and D2R bindings in the brain regions involved in the 
therapeutic effects of antipsychotics (Kuroki et al., 2008). The effects of co-treatment with 
O+B on 5-HT2AR binding is in line with our previous short-term study showed that both 
olanzapine-only and co-treatment of O+B have similar effects in decreasing 5-HT2AR binding 
density  (Lian et al., 2013). The present study also showed that both olanzapine-only and 
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O+B co-treatment has similar effects in attenuating 5-HT2CR and 5-HTT levels. Therefore, 
these results suggested that chronic O+B co-treatment does not affect olanzapine’s actions on 
5-HT neurotransmission. While up-regulation of D2R binding in the Cg, NAc, and CPu was 
observed in rats treated with chronic olanzapine treatment, chronic betahistine treatment 
decreased D2R binding density. Since the up-regulation of D2R binding is associated with 
“dopaminergic supersensitivity” (or “antipsychotic-induced supersensitivity psychosis”) that 
may lead to treatment failure over time (Samaha et al., 2007), the observation that O+B co-
treatment tends to reverse the up-regulation of D2R binding caused by chronic olanzapine 
treatment is promising for further investigation as whether co-treatment with betahistine can 
prevent the “dopaminergic supersensitivity” caused by chronic antipsychotic treatment.  
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                           Figure 1. Outline of the experimental design.  
 
 
 
  
Experimental design 
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